Boc-O-methyl-L-tyrosine

Boc-O-methyl-L-tyrosine is a protected tyrosine derivative in which the phenolic hydroxyl is methylated (O-methyl) and the amino group is protected as a Boc carbamate, making it a stable, bench-ready building block for peptide chemistry. The L-configuration at the alpha-carbon preserves stereochemical fidelity for downstream peptide assembly, while the O-methyl substituent reduces phenolic reactivity during coupling and allows controlled phenol handling later in synthetic workflows. This protected amino acid is commonly selected when tyrosine-like side-chain electronics and sterics are needed, but unprotected phenol chemistry is undesirable during synthesis or intermediate manufacturing.

1. Fmoc-Free Peptide Building Blocks

Boc-O-methyl-L-tyrosine is used by peptide synthesis groups that prefer Boc-protected amino acid chemistry for segment assembly and custom peptide manufacturing, including solution-phase and protecting-group-managed workflows. The Boc group provides an amino-protection strategy that remains compatible with typical peptide coupling conditions, while the O-methylated phenolic side chain helps prevent side reactions associated with free tyrosine phenols (such as undesired oxidation or electrophilic side chemistry) during fragment condensation. Researchers incorporate this residue into peptide sequences where a tyrosine-derived side chain is required but phenol reactivity must be suppressed until a later stage.

2. Tyrosine Side-Chain Protection Strategy

Boc-O-methyl-L-tyrosine is selected as a practical intermediate when a tyrosine-like aromatic side chain is needed under conditions where phenolic hydroxyl handling would complicate synthesis or purification. The O-methyl group functions as a stable phenol surrogate during peptide assembly, enabling chemists to maintain side-chain integrity while focusing on backbone construction. This makes the reagent useful for preparing peptide intermediates for downstream derivatization steps that require controlled phenol availability, such as later functionalization strategies performed after the peptide is assembled or after orthogonal deprotection planning in a multi-step sequence.

3. Pharmaceutical Intermediate Development

Boc-O-methyl-L-tyrosine is also used in medicinal chemistry and process development settings to generate tyrosine-derived protected fragments and peptide-like intermediates for structure-activity relationship studies. Teams developing peptidomimetic scaffolds or peptide conjugation precursors often choose this building block to manage reactivity during scale-up, because the protected phenolic side chain and Boc-protected amino functionality reduce the risk of premature side reactions in intermediate stages. The L-stereochemical configuration supports consistent stereochemical outcomes in downstream coupling or conversion steps, aligning with the requirements of synthetic chemistry programs that build toward defined, sequence-specific targets.

4. Analytical Reference for Protected Tyrosine Residues

Boc-O-methyl-L-tyrosine is used by analytical chemistry and method development teams as a defined, protected tyrosine derivative reference material for characterizing peptide intermediates and monitoring synthetic progress. Because it contains both a Boc-protected amino group and an O-methylated phenolic side chain, it provides a structurally unambiguous standard for LC-MS and related profiling workflows that distinguish protected tyrosine residues from free tyrosine or other phenol-protected analogs. This supports quality control of peptide synthesis inputs and helps interpret intermediate mixtures where protected tyrosine derivatives are expected to appear as discrete species.

1. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

2. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

3. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

5. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance